Data from National Health and Nutrition Examination Survey shows that US patients with obesity are at significantly high risk of experiencing chronic pain.

A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in obesity and knee osteoarthritis.

Recent results from a phase 3 clinical trial show that semaglutide may help reduce knee osteoarthritis-related pain in people with obesity. While these drugs are mainly used to help control type 2 ...

Semaglutide, better known as Ozempic and Wegovy, helped alleviate pain from knee osteoarthritis and improve function in patients with severe obesity, a new study found. The results of the 68 ...

This time around, Novo Nordisk's blockbuster treatment helped reduce knee pain in patients with a type of arthritis and obesity ... worked to bring systems back online and confirmed that files ...

Results from 68-week study of 407 adults with obesity and moderate knee osteoarthritis showed semaglutide 2.4 mg significantly reduced body weight, knee osteoarthritis-related pain, and improved ...

knee osteoarthritis-related pain, and improved physical function. Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with obesity and knee ...